RON ORDONA: Open Payments
NPI 1184050171 · LINCOLN, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,242 in 14 payments from 10 companies in 2025. Trend: 2023 $918 · 2024 $1,485 · 2025 $1,242
Food & beverage: $1,242
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $302 |
| Neurocrine BioSciences, Inc. | 2 | $278 |
| Incyte Corporation | 1 | $131 |
| AstraZeneca Pharmaceuticals LP | 1 | $123 |
| ALK-Abello, Inc | 1 | $119 |
| Alkermes, Inc. | 1 | $114 |
| Otsuka America Pharmaceutical, Inc. | 1 | $60 |
| Novo Nordisk Inc | 2 | $56 |
| Organogenesis Inc. | 1 | $45 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
Products named: AJOVY, TEZSPIRE, VIVITROL, INGREZZA, REXULTI, CYGNUS DUAL, Ozempic, Rybelsus.
Industry payments across CA — which companies pay providers there.
